These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25397509)

  • 1. Tolerability is more important than simplicity for treatment durability.
    Trottier B; Machouf N; Huchet E; Lavoie S; Vezina S; Boissonnault M; Charest L; Munoz M; Legault D; Longpré D; Thomas R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19765. PubMed ID: 25397509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
    d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
    HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.
    Cotte L; Ferry T; Pugliese P; Valantin MA; Allavena C; Cabié A; Poizot-Martin I; Rey D; Duvivier C; Cheret A; Dellamonica P; Pradat P; Parienti JJ;
    PLoS One; 2017; 12(2):e0170661. PubMed ID: 28152047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
    Marcelin AG; Charpentier C; Wirden M; Descamps D; Calvez V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19744. PubMed ID: 25397489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
    Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients.
    Casado JL; Bañón S; Moreno A; de Santiago AD; Gomez C; Perez-Elías MJ; Moreno S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19801. PubMed ID: 25397545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who gets single tablet regimens (STR), and why?
    Tarrier L; Kegg S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19777. PubMed ID: 25397521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
    Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.
    Cozzi-Lepri A; Lo Caputo S; Maggiolo F; Antinori A; Ammassari A; Marchetti G; Mastroianni C; Gori A; Di Perri G; Angarano G; Carbone A; Monforte Ad;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19775. PubMed ID: 25397519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19538. PubMed ID: 25394047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.